Trial Outcomes & Findings for Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults (NCT NCT03944954)

NCT ID: NCT03944954

Last Updated: 2024-04-05

Results Overview

Elasticity of Demand was measured by the Cannabis Purchase Task (CPT) where participants are asked how many "hits" of cannabis they would consume at 16 different price points in ascending order ($0-$140). Higher elasticity values indicate a greater sensitivity to changing price points resulting in a reduced demand for "hits" of THC at increasing price points.

Recruitment status

COMPLETED

Study phase

EARLY_PHASE1

Target enrollment

66 participants

Primary outcome timeframe

Measured 2 times: Baseline (0HR) and Post-TMS (3HR) after THC administration on each drug condition (0mg, 10mg, 30mg).

Results posted on

2024-04-05

Participant Flow

Forty young adults (N=40; n=20 per Experiment) aged 18-34 who report habitual cannabis use (20 or more days per month) or meet hazardous cannabis use criteria will complete the study. A 15% dropout rate is assumed. Subjects will be matched on sex, age and education. Enrollment will approximate the demographic proportions of Fayette County, KY. so we anticipate enrolling members mostly from those demographic categories.

Participant milestones

Participant milestones
Measure
Excitatory TMS
Combinations of active and placebo THC with real and sham excitatory TMS. Marinol: Individuals will receive 0, 10, 30mg of Marinol. Transcranial Magnetic Stimulation: Individuals will receive real or sham excitatory TMS.
Inhibitory TMS
Combinations of active and placebo THC with real and sham inhibitory TMS. Marinol: Individuals will receive 0, 10, 30mg of Marinol. Transcranial Magnetic Stimulation: Individuals will receive real and sham inhibitory TMS.
Overall Study
STARTED
58
8
Overall Study
Training Session
24
5
Overall Study
0mg Marinol Sham TMS
13
4
Overall Study
0mg Marinol Real TMS
14
4
Overall Study
10mg Marinol Sham TMS
13
4
Overall Study
10mg Marinol Real TMS
12
4
Overall Study
30mg Marinol Sham TMS
12
5
Overall Study
30mg Marinol Real TMS
12
4
Overall Study
COMPLETED
11
4
Overall Study
NOT COMPLETED
47
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Excitatory TMS
Combinations of active and placebo THC with real and sham excitatory TMS. Marinol: Individuals will receive 0, 10, 30mg of Marinol. Transcranial Magnetic Stimulation: Individuals will receive real or sham excitatory TMS.
Inhibitory TMS
Combinations of active and placebo THC with real and sham inhibitory TMS. Marinol: Individuals will receive 0, 10, 30mg of Marinol. Transcranial Magnetic Stimulation: Individuals will receive real and sham inhibitory TMS.
Overall Study
Withdrawal by Subject
22
4
Overall Study
Lost to Follow-up
18
0
Overall Study
Failed Medical Screening
7
0

Baseline Characteristics

Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Excitatory TMS
n=58 Participants
Combinations of THC and excitatory TMS. Marinol: Individuals will receive 0, 10, 30mg of Marinol. Transcranial Magnetic Stimulation: Individuals will receive real and sham TMS
Inhibitory TMS
n=8 Participants
Combinations of THC and inhibitory TMS. Marinol: Individuals will receive 0, 10, 30mg of Marinol. Transcranial Magnetic Stimulation: Individuals will receive real and sham TMS
Total
n=66 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
58 Participants
n=99 Participants
8 Participants
n=107 Participants
66 Participants
n=206 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Continuous
22.8 years
STANDARD_DEVIATION 4.5 • n=99 Participants
27 years
STANDARD_DEVIATION 7.0 • n=107 Participants
23.8 years
STANDARD_DEVIATION 5.3 • n=206 Participants
Sex: Female, Male
Female
13 Participants
n=99 Participants
3 Participants
n=107 Participants
16 Participants
n=206 Participants
Sex: Female, Male
Male
45 Participants
n=99 Participants
5 Participants
n=107 Participants
50 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
57 Participants
n=99 Participants
8 Participants
n=107 Participants
65 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
3 Participants
n=99 Participants
0 Participants
n=107 Participants
3 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
15 Participants
n=99 Participants
1 Participants
n=107 Participants
16 Participants
n=206 Participants
Race (NIH/OMB)
White
37 Participants
n=99 Participants
7 Participants
n=107 Participants
44 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
n=99 Participants
0 Participants
n=107 Participants
3 Participants
n=206 Participants
Region of Enrollment
United States
58 participants
n=99 Participants
8 participants
n=107 Participants
66 participants
n=206 Participants

PRIMARY outcome

Timeframe: Measure collected at 2 time points: Baseline (0HR) and Post TMS Administration (3HR)

Population: Of the 58 total participants assigned to the excitatory TMS condition, 15 individuals completed at least one experimental session. Of the 8 total participants assigned to the inhibitory TMS condition, 6 individuals completed at least one experimental session.

In a Probabilistic Reinforcement Learning Choice (PRLC) task, two stimuli are presented and choosing either could result in a monetary reinforcer, but the reinforcement probabilities of the stimuli differ, and change throughout the task. Individuals attempt to optimize choices according to learned probabilities and track changing probabilities over time. PRLC performance allows mathematical modeling of trial-by-trial data under "real-world" uncertainty and yields computational parameters, such as the learning rate. Choice data were analyzed using a Rescorla-Wanger learning model with an alpha learning rate, beta inverse temperature, and perseveration global parameters. Model-derived learning rates are indicative of an individual's ability to learn from previous choice outcomes to update future decision-making. For this task, learning rates range from 0-1 with lower values indicative of more optimal learning.

Outcome measures

Outcome measures
Measure
Excitatory TMS
n=15 Participants
Individuals assigned to this group will receive excitatory (real and sham) TMS in combination with 0, 10, and 30mg THC. Placebo TMS Sham: Individuals will receive placebo dose and sham TMS. Marinol 10Mg Capsule TMS Sham: Individuals will receive 10mg dose and sham TMS. Marinol 30Mg Capsule TMS Sham: Individuals will receive 30mg dose and sham TMS. Placebo TMS Real: Individuals will receive placebo and real TMS. Marinol 10Mg Capsule TMS Real: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention) Marinol 30Mg Capsule TMS Real: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Inhibitory TMS
n=6 Participants
Individuals assigned to this group will receive inhibitory (real and sham) TMS in combination with 0, 10, and 30mg THC. Placebo TMS Sham: Individuals will receive placebo dose and sham TMS. Marinol 10Mg Capsule TMS Sham: Individuals will receive 10mg dose and sham TMS. Marinol 30Mg Capsule TMS Sham: Individuals will receive 30mg dose and sham TMS. Placebo TMS Real: Individuals will receive placebo and real TMS. Marinol 10Mg Capsule TMS Real: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention) Marinol 30Mg Capsule TMS Real: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Alpha Learning Rate
Baseline 0mg Sham
.62 Alpha Coefficient
Standard Deviation .28
.43 Alpha Coefficient
Standard Deviation .37
Alpha Learning Rate
3HR 0mg Sham
.55 Alpha Coefficient
Standard Deviation .31
.21 Alpha Coefficient
Standard Deviation .23
Alpha Learning Rate
Baseline 0mg Real
.71 Alpha Coefficient
Standard Deviation .27
.53 Alpha Coefficient
Standard Deviation .41
Alpha Learning Rate
3HR 0mg Real
.58 Alpha Coefficient
Standard Deviation .33
.48 Alpha Coefficient
Standard Deviation .34
Alpha Learning Rate
Baseline 10mg Sham
.62 Alpha Coefficient
Standard Deviation .32
.49 Alpha Coefficient
Standard Deviation .15
Alpha Learning Rate
3HR 10mg Sham
.62 Alpha Coefficient
Standard Deviation .28
.52 Alpha Coefficient
Standard Deviation .41
Alpha Learning Rate
Baseline 10mg Real
.63 Alpha Coefficient
Standard Deviation .27
.53 Alpha Coefficient
Standard Deviation .38
Alpha Learning Rate
3HR 10mg Real
.63 Alpha Coefficient
Standard Deviation .28
.32 Alpha Coefficient
Standard Deviation .38
Alpha Learning Rate
Baseline 30mg Sham
.64 Alpha Coefficient
Standard Deviation .29
.48 Alpha Coefficient
Standard Deviation .37
Alpha Learning Rate
3HR 30mg Sham
.60 Alpha Coefficient
Standard Deviation .29
.41 Alpha Coefficient
Standard Deviation .30
Alpha Learning Rate
Baseline 30mg Real
.66 Alpha Coefficient
Standard Deviation .32
.24 Alpha Coefficient
Standard Deviation .16
Alpha Learning Rate
3HR 30mg Real
.79 Alpha Coefficient
Standard Deviation .17
.30 Alpha Coefficient
Standard Deviation .22

PRIMARY outcome

Timeframe: Measured 2 times: Baseline (0HR) and 3 hours (3HR) after capsule administration on each drug condition (0mg, 10mg, 30mg)

Population: Of the 58 participants assigned to the Excitatory TMS condition, as max of 14 participants had usable data from at least one experimental session. Of the 8 participants assigned to the Inhibitory TMS condition, as max of 4 participants had usable data from at least one experimental session.

A Visual Analogue Scale (VAS) was used to measure the acute subjective effects of THC at varying doses (0mg, 10mg, 30mg). Responses are made for VAS items along a 100-unit scale anchored on the extremes by "Not At All" (0) and "Extremely" (100) with a higher score meaning more of the effect. Participants were instructed to select "Not At All" (0) for all baseline (0HR) measures. Post-TMS administration (real or sham), participant self-reported their subjective "high" on the VAS with higher values indicating a more intense sensation of "high".

Outcome measures

Outcome measures
Measure
Excitatory TMS
n=14 Participants
Individuals assigned to this group will receive excitatory (real and sham) TMS in combination with 0, 10, and 30mg THC. Placebo TMS Sham: Individuals will receive placebo dose and sham TMS. Marinol 10Mg Capsule TMS Sham: Individuals will receive 10mg dose and sham TMS. Marinol 30Mg Capsule TMS Sham: Individuals will receive 30mg dose and sham TMS. Placebo TMS Real: Individuals will receive placebo and real TMS. Marinol 10Mg Capsule TMS Real: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention) Marinol 30Mg Capsule TMS Real: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Inhibitory TMS
n=4 Participants
Individuals assigned to this group will receive inhibitory (real and sham) TMS in combination with 0, 10, and 30mg THC. Placebo TMS Sham: Individuals will receive placebo dose and sham TMS. Marinol 10Mg Capsule TMS Sham: Individuals will receive 10mg dose and sham TMS. Marinol 30Mg Capsule TMS Sham: Individuals will receive 30mg dose and sham TMS. Placebo TMS Real: Individuals will receive placebo and real TMS. Marinol 10Mg Capsule TMS Real: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention) Marinol 30Mg Capsule TMS Real: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Self-Report Subjective "High"
"High" 0mg THC Real TMS
2.9 score on a 100pt VAS scale
Standard Deviation 5.4
0 score on a 100pt VAS scale
Standard Deviation 0
Self-Report Subjective "High"
"High" 10mg THC Real TMS
13.8 score on a 100pt VAS scale
Standard Deviation 24.4
3.8 score on a 100pt VAS scale
Standard Deviation 7.5
Self-Report Subjective "High"
"High" 30mg THC Real TMS
24.6 score on a 100pt VAS scale
Standard Deviation 27.3
5 score on a 100pt VAS scale
Standard Deviation 10
Self-Report Subjective "High"
"High" 0mg THC Sham TMS
1.2 score on a 100pt VAS scale
Standard Deviation 2.2
3.8 score on a 100pt VAS scale
Standard Deviation 7.5
Self-Report Subjective "High"
"High" 10mg THC Sham TMS
15 score on a 100pt VAS scale
Standard Deviation 20.3
1.3 score on a 100pt VAS scale
Standard Deviation 2.5
Self-Report Subjective "High"
"High" 30mg THC Sham TMS
36.5 score on a 100pt VAS scale
Standard Deviation 32
12.5 score on a 100pt VAS scale
Standard Deviation 21.8

PRIMARY outcome

Timeframe: Measured 2 times: Baseline (0HR) and Post-TMS (3HR) after THC administration on each drug condition (0mg, 10mg, 30mg).

Population: Of the 58 participants assigned to the excitatory TMS condition, 13 individuals had usable data from at least one experimental session. Of the 8 participants assigned to the excitatory TMS condition, 4 individuals had usable data from at least one experimental session.

Elasticity of Demand was measured by the Cannabis Purchase Task (CPT) where participants are asked how many "hits" of cannabis they would consume at 16 different price points in ascending order ($0-$140). Higher elasticity values indicate a greater sensitivity to changing price points resulting in a reduced demand for "hits" of THC at increasing price points.

Outcome measures

Outcome measures
Measure
Excitatory TMS
n=13 Participants
Individuals assigned to this group will receive excitatory (real and sham) TMS in combination with 0, 10, and 30mg THC. Placebo TMS Sham: Individuals will receive placebo dose and sham TMS. Marinol 10Mg Capsule TMS Sham: Individuals will receive 10mg dose and sham TMS. Marinol 30Mg Capsule TMS Sham: Individuals will receive 30mg dose and sham TMS. Placebo TMS Real: Individuals will receive placebo and real TMS. Marinol 10Mg Capsule TMS Real: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention) Marinol 30Mg Capsule TMS Real: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Inhibitory TMS
n=4 Participants
Individuals assigned to this group will receive inhibitory (real and sham) TMS in combination with 0, 10, and 30mg THC. Placebo TMS Sham: Individuals will receive placebo dose and sham TMS. Marinol 10Mg Capsule TMS Sham: Individuals will receive 10mg dose and sham TMS. Marinol 30Mg Capsule TMS Sham: Individuals will receive 30mg dose and sham TMS. Placebo TMS Real: Individuals will receive placebo and real TMS. Marinol 10Mg Capsule TMS Real: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention) Marinol 30Mg Capsule TMS Real: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Elasticity of Demand
Baseline 0mg THC Real TMS
.005 log(hits per dollar)
Standard Deviation .008
.004 log(hits per dollar)
Standard Deviation .003
Elasticity of Demand
3HR 0mg THC Real TMS
.006 log(hits per dollar)
Standard Deviation .009
.007 log(hits per dollar)
Standard Deviation .007
Elasticity of Demand
Baseline 10mg THC Real TMS
.005 log(hits per dollar)
Standard Deviation .008
.003 log(hits per dollar)
Standard Deviation .002
Elasticity of Demand
3HR 10mg THC Real TMS
.006 log(hits per dollar)
Standard Deviation .009
.002 log(hits per dollar)
Standard Deviation .001
Elasticity of Demand
Baseline 30mg THC Real TMS
.004 log(hits per dollar)
Standard Deviation .002
.005 log(hits per dollar)
Standard Deviation .003
Elasticity of Demand
3HR 30mg THC Real TMS
.006 log(hits per dollar)
Standard Deviation .008
.000 log(hits per dollar)
Standard Deviation .000
Elasticity of Demand
Baseline 0mg THC Sham TMS
.005 log(hits per dollar)
Standard Deviation .009
.005 log(hits per dollar)
Standard Deviation .006
Elasticity of Demand
3HR 0mg THC Sham TMS
.005 log(hits per dollar)
Standard Deviation .009
.006 log(hits per dollar)
Standard Deviation .009
Elasticity of Demand
Baseline 10mg THC Sham TMS
.006 log(hits per dollar)
Standard Deviation .009
.004 log(hits per dollar)
Standard Deviation .002
Elasticity of Demand
3HR 10mg THC Sham TMS
.005 log(hits per dollar)
Standard Deviation .009
.003 log(hits per dollar)
Standard Deviation .002
Elasticity of Demand
Baseline 30mg THC Sham TMS
.004 log(hits per dollar)
Standard Deviation .004
.004 log(hits per dollar)
Standard Deviation .004
Elasticity of Demand
3HR 30mg THC Sham TMS
.005 log(hits per dollar)
Standard Deviation .006
.007 log(hits per dollar)
Standard Deviation .007

PRIMARY outcome

Timeframe: Measured 2 times: Baseline (0HR) and Post-TMS (3HR) after THC administration on each drug condition (0mg, 10mg, 30mg).

Population: Of the 58 participants assigned to the excitatory TMS condition, 14 individuals had usable data from at least one experimental session. Of the 8 participants assigned to the excitatory TMS condition, 4 individuals had usable data from at least one experimental session.

Working memory (WM), the ability to hold a finite amount of information for a set amount of time, is measured by the N-Back task. Here, participants were presented with a sequence of letters and must indicate when the letter currently being viewed matches the one from N steps earlier in the sequence. The load factor "N" is adjusted between 0, 1, and 2 to adjust the difficulty of the task (0-Back = no WM load, 1-Back = minimal WM load, 2-Back = greater WM load) where a higher score means better memory performance. Outcomes are reported as the Total Accuracy Percentage (Correct Choices/Total Choices) x 100%

Outcome measures

Outcome measures
Measure
Excitatory TMS
n=14 Participants
Individuals assigned to this group will receive excitatory (real and sham) TMS in combination with 0, 10, and 30mg THC. Placebo TMS Sham: Individuals will receive placebo dose and sham TMS. Marinol 10Mg Capsule TMS Sham: Individuals will receive 10mg dose and sham TMS. Marinol 30Mg Capsule TMS Sham: Individuals will receive 30mg dose and sham TMS. Placebo TMS Real: Individuals will receive placebo and real TMS. Marinol 10Mg Capsule TMS Real: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention) Marinol 30Mg Capsule TMS Real: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Inhibitory TMS
n=4 Participants
Individuals assigned to this group will receive inhibitory (real and sham) TMS in combination with 0, 10, and 30mg THC. Placebo TMS Sham: Individuals will receive placebo dose and sham TMS. Marinol 10Mg Capsule TMS Sham: Individuals will receive 10mg dose and sham TMS. Marinol 30Mg Capsule TMS Sham: Individuals will receive 30mg dose and sham TMS. Placebo TMS Real: Individuals will receive placebo and real TMS. Marinol 10Mg Capsule TMS Real: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention) Marinol 30Mg Capsule TMS Real: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Working Memory Performance
Baseline 0back 0mg THC Real TMS
98.0 percentage of correct choices
Standard Deviation 1.7
96.3 percentage of correct choices
Standard Deviation 4.3
Working Memory Performance
Baseline 1back 0mg THC Real TMS
93.0 percentage of correct choices
Standard Deviation 4.2
90 percentage of correct choices
Standard Deviation 12.4
Working Memory Performance
Baseline 2back 0mg THC Real TMS
90.1 percentage of correct choices
Standard Deviation 4.7
86.3 percentage of correct choices
Standard Deviation 21.4
Working Memory Performance
Baseline 0back 10mg THC Real TMS
97.1 percentage of correct choices
Standard Deviation 3.4
98.3 percentage of correct choices
Standard Deviation 1.4
Working Memory Performance
Baseline 2back 10mg THC Real TMS
90.2 percentage of correct choices
Standard Deviation 4.9
93.3 percentage of correct choices
Standard Deviation 7.6
Working Memory Performance
Baseline 1back 10mg THC Real TMS
93.3 percentage of correct choices
Standard Deviation 4.3
93.3 percentage of correct choices
Standard Deviation 3.8
Working Memory Performance
Baseline 0back 30mg THC Real TMS
97.7 percentage of correct choices
Standard Deviation 2.2
98.1 percentage of correct choices
Standard Deviation 1.3
Working Memory Performance
Baseline 1back 30mg THC Real TMS
92.5 percentage of correct choices
Standard Deviation 3.68
85 percentage of correct choices
Standard Deviation 21.7
Working Memory Performance
Baseline 2back 30mg THC Real TMS
89.2 percentage of correct choices
Standard Deviation 5.5
87.5 percentage of correct choices
Standard Deviation 14.3
Working Memory Performance
Baseline 0back 0mg THC Sham TMS
98.1 percentage of correct choices
Standard Deviation 2.2
96.9 percentage of correct choices
Standard Deviation 3.2
Working Memory Performance
Baseline 1back 0mgTHC Sham TMS
92.1 percentage of correct choices
Standard Deviation 4.8
89.4 percentage of correct choices
Standard Deviation 11.3
Working Memory Performance
Baseline 2back 0mg THC Sham TMS
88.3 percentage of correct choices
Standard Deviation 4.3
85.0 percentage of correct choices
Standard Deviation 21.4
Working Memory Performance
Baseline 0back 10mg THC Sham TMS
96.4 percentage of correct choices
Standard Deviation 3.8
93.1 percentage of correct choices
Standard Deviation 12.1
Working Memory Performance
Baseline 1back 10mg THC Sham TMS
92.1 percentage of correct choices
Standard Deviation 4.9
92.5 percentage of correct choices
Standard Deviation 10.2
Working Memory Performance
Baseline 2back 10mg THC Sham TMS
87.9 percentage of correct choices
Standard Deviation 6.4
83.8 percentage of correct choices
Standard Deviation 19.7
Working Memory Performance
Baseline 0back 30mg THC Sham TMS
96.5 percentage of correct choices
Standard Deviation 3.5
96.3 percentage of correct choices
Standard Deviation 2.5
Working Memory Performance
Baseline 1back 30mg THC Sham TMS
95 percentage of correct choices
Standard Deviation 2.8
90.6 percentage of correct choices
Standard Deviation 5.5
Working Memory Performance
Baseline 2back 30mg THC Sham TMS
86.9 percentage of correct choices
Standard Deviation 6.9
87.5 percentage of correct choices
Standard Deviation 12.6
Working Memory Performance
3HR 0back 0mg THC Real TMS
97.5 percentage of correct choices
Standard Deviation 3.4
96.7 percentage of correct choices
Standard Deviation 3.2
Working Memory Performance
3HR 1back 0mg THC Real TMS
91.4 percentage of correct choices
Standard Deviation 3.1
92.5 percentage of correct choices
Standard Deviation 3.5
Working Memory Performance
3HR 2back 0mg THC Real TMS
87.3 percentage of correct choices
Standard Deviation 5.8
89.4 percentage of correct choices
Standard Deviation 13.6
Working Memory Performance
3HR 0back 10mg THC Real TMS
96.7 percentage of correct choices
Standard Deviation 3.1
98.3 percentage of correct choices
Standard Deviation 1.4
Working Memory Performance
3HR 1back 10mg THC Real TMS
92.5 percentage of correct choices
Standard Deviation 4.9
97.5 percentage of correct choices
Standard Deviation 4.3
Working Memory Performance
3HR 2back 10mg THC Real TMS
87.3 percentage of correct choices
Standard Deviation 7.5
95 percentage of correct choices
Standard Deviation 6.6
Working Memory Performance
3HR 0back 30mg THC Real TMS
96.7 percentage of correct choices
Standard Deviation 3.6
98.1 percentage of correct choices
Standard Deviation 2.4
Working Memory Performance
3HR 1back 30mg THC Real TMS
88.3 percentage of correct choices
Standard Deviation 7.4
90.6 percentage of correct choices
Standard Deviation 5.2
Working Memory Performance
3HR 2back 30mg THC Real TMS
86.9 percentage of correct choices
Standard Deviation 5.9
90.6 percentage of correct choices
Standard Deviation 8.8
Working Memory Performance
3HR 0back 0mg THC Sham TMS
96.7 percentage of correct choices
Standard Deviation 4.1
97.5 percentage of correct choices
Standard Deviation 2.0
Working Memory Performance
3HR 1back 0mg THC Sham TMS
91.7 percentage of correct choices
Standard Deviation 5.6
93.8 percentage of correct choices
Standard Deviation 7.8
Working Memory Performance
3HR 2back 0mg THC Sham TMS
89.0 percentage of correct choices
Standard Deviation 6.0
87.5 percentage of correct choices
Standard Deviation 10.6
Working Memory Performance
3HR 0back 10mg THC Sham TMS
96.2 percentage of correct choices
Standard Deviation 3.0
90 percentage of correct choices
Standard Deviation 18.4
Working Memory Performance
3HR 1back 10mg THC Sham TMS
92.3 percentage of correct choices
Standard Deviation 5.5
85.6 percentage of correct choices
Standard Deviation 19.1
Working Memory Performance
3HR 2back 10mg THC Sham TMS
88.5 percentage of correct choices
Standard Deviation 7.0
82.5 percentage of correct choices
Standard Deviation 23.8
Working Memory Performance
3HR 0back 30mg THC Sham TMS
96.7 percentage of correct choices
Standard Deviation 3.7
94.4 percentage of correct choices
Standard Deviation 3.8
Working Memory Performance
3HR 1back 30mg THC Sham TMS
92.9 percentage of correct choices
Standard Deviation 3.2
91.3 percentage of correct choices
Standard Deviation 7.5
Working Memory Performance
3HR 2back 30mg THC Sham TMS
87.3 percentage of correct choices
Standard Deviation 8.5
87.5 percentage of correct choices
Standard Deviation 14.9

Adverse Events

0mg Marinol

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

10mg Marinol

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

30mg Marinol

Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
0mg Marinol
n=18 participants at risk
Marinol: Individuals will receive 0mg Marinol. Transcranial Magnetic Stimulation: Individuals will receive either excitatory or inhibitory TMS.
10mg Marinol
n=17 participants at risk
Marinol: Individuals will receive 10mg Marinol. Transcranial Magnetic Stimulation: Individuals will receive either excitatory or inhibitory TMS.
30mg Marinol
n=17 participants at risk
Marinol: Individuals will receive 30mg Marinol. Transcranial Magnetic Stimulation: Individuals will receive either excitatory or inhibitory TMS.
Injury, poisoning and procedural complications
Headaches
5.6%
1/18 • Number of events 1 • 1 day
0.00%
0/17 • 1 day
0.00%
0/17 • 1 day

Additional Information

Dr. Michael J Wesley

University of Kentucky

Phone: 8593230579

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place